Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207414> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4387207414 endingPage "e355" @default.
- W4387207414 startingPage "e355" @default.
- W4387207414 abstract "For locally advanced biliary tract cancer (BTC), capecitabine-based chemoradiotherapy (CRT) is commonly used but has limited benefits. Immunotherapy is potentially effective for BTC and may be synergized with CRT. Followed by gemcitabine and cisplatin (GP) consolidation chemotherapy (CT), we evaluated the safety and efficacy of combined camrelizumab and capecitabine-based CRT for locally advanced BTC.Patients had stage II-III (T4N0M0, T1-4N+M0) BTC (per the 7th [2010] edition of the American Joint Committee on Cancer staging system) were eligible for CRT (capecitabine plus [50-60 Gy] radiotherapy), to be followed by GP CT. Camrelizumab was given concurrently with CRT. Safety was defined as the incidence and severity of adverse events (AEs), while efficacy was defined as overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR).Ten patients completed the planned treatment. None experienced grade ≥3 treatment-related AEs during CRT. Grade ≥3 immune-related AEs occurred in 2 of 10 patients (20%) only during GP CT. The mean OS time was 18.2 months (95% confidence interval [CI] 12.9m-23.5m) while the median OS time was 14.1 months (95% CI 10.1m-18.1m). OS rates were 100%, 59%, 44% at 6 months, 1 year and 2 years, respectively. The ORR was 30% while the DCR was 90%. Two patients (20%) obtained OS over 2 years with partial response (25.9m, 29.1m). Median PFS time was 14.1 months (95% CI 9.3m-18.9m).Camrelizumab in combination with concurrent CRT was well tolerated and did not impair delivery of CRT in patients with locally advanced BTC." @default.
- W4387207414 created "2023-09-30" @default.
- W4387207414 creator A5035062625 @default.
- W4387207414 creator A5035282947 @default.
- W4387207414 creator A5042973046 @default.
- W4387207414 creator A5059032368 @default.
- W4387207414 creator A5064496142 @default.
- W4387207414 creator A5081403581 @default.
- W4387207414 creator A5085409628 @default.
- W4387207414 creator A5085724915 @default.
- W4387207414 creator A5086510706 @default.
- W4387207414 date "2023-10-01" @default.
- W4387207414 modified "2023-10-04" @default.
- W4387207414 title "Camrelizumab with Chemoradiotherapy for Locally Advanced Biliary Tract Cancer: Preliminary Results from A Phase II Study" @default.
- W4387207414 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2434" @default.
- W4387207414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785226" @default.
- W4387207414 hasPublicationYear "2023" @default.
- W4387207414 type Work @default.
- W4387207414 citedByCount "0" @default.
- W4387207414 crossrefType "journal-article" @default.
- W4387207414 hasAuthorship W4387207414A5035062625 @default.
- W4387207414 hasAuthorship W4387207414A5035282947 @default.
- W4387207414 hasAuthorship W4387207414A5042973046 @default.
- W4387207414 hasAuthorship W4387207414A5059032368 @default.
- W4387207414 hasAuthorship W4387207414A5064496142 @default.
- W4387207414 hasAuthorship W4387207414A5081403581 @default.
- W4387207414 hasAuthorship W4387207414A5085409628 @default.
- W4387207414 hasAuthorship W4387207414A5085724915 @default.
- W4387207414 hasAuthorship W4387207414A5086510706 @default.
- W4387207414 hasConcept C121608353 @default.
- W4387207414 hasConcept C126322002 @default.
- W4387207414 hasConcept C141071460 @default.
- W4387207414 hasConcept C143998085 @default.
- W4387207414 hasConcept C197934379 @default.
- W4387207414 hasConcept C2776694085 @default.
- W4387207414 hasConcept C2777909004 @default.
- W4387207414 hasConcept C2778424827 @default.
- W4387207414 hasConcept C2780258809 @default.
- W4387207414 hasConcept C2780739268 @default.
- W4387207414 hasConcept C509974204 @default.
- W4387207414 hasConcept C526805850 @default.
- W4387207414 hasConcept C71924100 @default.
- W4387207414 hasConcept C90924648 @default.
- W4387207414 hasConceptScore W4387207414C121608353 @default.
- W4387207414 hasConceptScore W4387207414C126322002 @default.
- W4387207414 hasConceptScore W4387207414C141071460 @default.
- W4387207414 hasConceptScore W4387207414C143998085 @default.
- W4387207414 hasConceptScore W4387207414C197934379 @default.
- W4387207414 hasConceptScore W4387207414C2776694085 @default.
- W4387207414 hasConceptScore W4387207414C2777909004 @default.
- W4387207414 hasConceptScore W4387207414C2778424827 @default.
- W4387207414 hasConceptScore W4387207414C2780258809 @default.
- W4387207414 hasConceptScore W4387207414C2780739268 @default.
- W4387207414 hasConceptScore W4387207414C509974204 @default.
- W4387207414 hasConceptScore W4387207414C526805850 @default.
- W4387207414 hasConceptScore W4387207414C71924100 @default.
- W4387207414 hasConceptScore W4387207414C90924648 @default.
- W4387207414 hasIssue "2" @default.
- W4387207414 hasLocation W43872074141 @default.
- W4387207414 hasLocation W43872074142 @default.
- W4387207414 hasOpenAccess W4387207414 @default.
- W4387207414 hasPrimaryLocation W43872074141 @default.
- W4387207414 hasRelatedWork W2139955290 @default.
- W4387207414 hasRelatedWork W2382613782 @default.
- W4387207414 hasRelatedWork W2391084975 @default.
- W4387207414 hasRelatedWork W2404042595 @default.
- W4387207414 hasRelatedWork W2419408601 @default.
- W4387207414 hasRelatedWork W3007914843 @default.
- W4387207414 hasRelatedWork W3029737226 @default.
- W4387207414 hasRelatedWork W3031015708 @default.
- W4387207414 hasRelatedWork W4386225391 @default.
- W4387207414 hasRelatedWork W4386225412 @default.
- W4387207414 hasVolume "117" @default.
- W4387207414 isParatext "false" @default.
- W4387207414 isRetracted "false" @default.
- W4387207414 workType "article" @default.